Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.

International journal of cancer - 15 Feb 2009

Ashida Atsuko, Takata Minoru, Murata Hiroshi, Kido Kenji, Saida Toshiaki

Abstract excerpt

Recent studies showed KIT gene aberrations in a substantial number of melanomas on acral skin and mucosa, suggesting the therapeutic benefit of tyrosine kinase inhibitors, such as imatinib. We therefore examined the expression and mutations of KIT in 4 primary and 24 metastatic acral and mucosal melanomas. Immunohistochemistry revealed moderate or strong KIT protein expression in 13 (48%) tumors. Sequence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Mucous Membrane
Share to Neoplasm Metastasis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Skin Neoplasms

Share to Stem Cell Factor

Share to Sunitinib

Source

Identifiers

PMID: 19035443
DOI: 10.1002/ijc.24048

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.PMID 19035443Read ↗

Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations.Semantic proximity Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

KIT gene mutations and patterns of protein expression in mucosal and acral melanoma.Semantic proximity Read ↗

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Semantic proximity Read ↗

Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.Semantic proximity Read ↗

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

Somatic Activation of KIT in Distinct Subtypes of MelanomaSemantic proximity Read ↗

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.Semantic proximity Read ↗

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.Semantic proximity Read ↗

Imatinib targeting of KIT-mutant oncoprotein in melanoma.Semantic proximity Read ↗

KIT amplification and gene mutations in acral/mucosal melanoma in Korea.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.